Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

NCT07722741 is registered in ClinicalTrials.gov with Geneos Therapeutics as lead sponsor.

NCT NCT07722741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07722741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
Lead sponsor
Geneos Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
June 30, 2032
Enrollment
90 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hcc